RxDoctor Payments Data

Dulcimina Welsh, APRN

Psychiatric/Mental Health · Meriden, CTNPI 1780292706

Payments from drug & device makers

$1,641in general payments, 2019–2025

Across 80 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$433
  • Alkermes, Inc.$303
  • Teva Pharmaceuticals USA, Inc.$206
  • Johnson & Johnson$134
  • AbbVie$132
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$97
  • plus $335 from 7 others

What the payments were for

  • Food & beverage$1,641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,641 in reported general payments places this provider in the 80th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$2,615
Medicare patients
22
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$28,015
Clozapine13$2,508
Lurasidone Hcl15$1,557
Quetiapine Fumarate36$702
Mirtazapine30$512
Divalproex Sodium11$468
Benztropine Mesylate27$398
Hydroxyzine Hcl24$389
Trazodone Hcl73$381
Divalproex Sodium ErDivalproex Sodium11$312
Buspirone Hcl22$282
Olanzapine25$247
Bupropion Hcl SrBupropion Hcl12$212
Bupropion XlBupropion Hcl20$205
Aripiprazole12$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$132$28,01518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →